RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- Envisia Therapeutics today announced that it will present data for its next generation product candidates, ENV515 for glaucoma and ENV705 for age-related macular degeneration (AMD), as well as new data for the company’s novel drug delivery systems designed for the posterior and anterior segments of the eye, at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting. ARVO is globally recognized and respected as a leading provider of quality content and research, and the annual meeting is the industry’s premier gathering place for information exchange and networking. ARVO 2014 is being held May 4-8, 2014, in Orlando, FL.
“Envisia is extremely proud to have such a great showing of data at the ARVO 2014 Annual Meeting, which is revered by both scientists and practitioners internationally,” said Ben Yerxa, Ph.D., Chief Scientific Officer of Envisia. “We believe our technology provides a white space of opportunity that will pave the way for the next generation of ophthalmology products that have the potential to improve patient safety and outcomes.”
Tomas Navratil, Ph.D., Envisia’s Vice President of Development, will give an oral presentation titled Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action on Tuesday May 6th at 4:15PM in Room S310A-D.
In addition, the company will present data supporting the following abstracts titled:
Post-operative Inflammation and Pain:
Envisia uses the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats.
Envisia’s lead product, ENV515, is a marketed prostaglandin analogue that uses a proprietary, fully biodegradable PRINT particle formulation to provide sustained intraocular pressure (IOP) reduction over many months, offering the potential to address the poor compliance that exists today and to limit glaucoma progression and vision loss. Envisia is also exploring how the company’s unique technology can address other important ocular diseases, such as AMD and ocular inflammation.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.